Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Office ...